Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-04

AUTHORS

M. Inouye, T. Mio, K. Sumino

ABSTRACT

Objective: Nilvadipine, a calcium antagonist, has been shown to have antioxidant activity in vitro, but its effect on in vivo oxidation has not been assessed. The aim of this study was to investigate the antioxidant effect of this agent in vivo. The ratios of 7-keto cholestadien to cholesterol are believed to be an available marker of lipid peroxidation. Using these ratios, we have assessed the antioxidant effect of nilvadipine on low-density lipoprotein (LDL) in hypertensive patients with high risk of atherosclerosis. The risk factors of atherosclerosis may involve oxidation of LDL.Methods: Fifteen healthy subjects (seven females and eight males aged 35–72 years, mean ± SD=55.3 ± 13.8 years) and fifteen hypertensive patients (seven females and eight males aged 45–80 years, mean ± SD = 60.2 ± 11.8 years) were recruited. Patients were treated orally with nilvadipine (4 mg b.i.d.) for 4 weeks. Cholesterol oxidation levels of LDL in patients before and after nilvadipine therapy and healthy subjects were studied.Results: The ratios of 7-keto cholestadien to cholesterol in LDL of hypertensive patients before and 4 weeks after nilvadipine treatment and in healthy subjects were 6.5 ± 1.6% (mean ± SD), 3.8 ± 1.2%, and 0.2 ± 0.1%, respectively. There were significantly (P < 0.001) increased levels of cholesterol oxidation in LDL in patients with hypertension both before and after nilvadipine treatment compared with healthy subjects. However, there was a significantly (P < 0.001) decreased level of cholesterol oxidation in LDL in patients after nilvadipine treatment compared with patients before nilvadipine treatment.Conclusion: Our data showed that nilvadipine may protect LDL cholesterol from in vivo oxidation in hypertensive patients with high risk of atherosclerosis. More... »

PAGES

35-41

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002280050717

DOI

http://dx.doi.org/10.1007/s002280050717

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046077486

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10853875


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arteriosclerosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nifedipine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxidative Stress", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Akebono-cho 1070, Nishi-ku, Kobe 651-2181, Japan Tel.: +81-78-9272727; Fax: +81-78-9259203, JP", 
          "id": "http://www.grid.ac/institutes/grid.413722.1", 
          "name": [
            "Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Akebono-cho 1070, Nishi-ku, Kobe 651-2181, Japan Tel.: +81-78-9272727; Fax: +81-78-9259203, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inouye", 
        "givenName": "M.", 
        "id": "sg:person.01052526706.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052526706.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP", 
          "id": "http://www.grid.ac/institutes/grid.31432.37", 
          "name": [
            "Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mio", 
        "givenName": "T.", 
        "id": "sg:person.01303203706.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303203706.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP", 
          "id": "http://www.grid.ac/institutes/grid.31432.37", 
          "name": [
            "Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sumino", 
        "givenName": "K.", 
        "id": "sg:person.0625412514.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625412514.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00051106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047626214", 
          "https://doi.org/10.1007/bf00051106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02940252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051361641", 
          "https://doi.org/10.1007/bf02940252"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-04", 
    "datePublishedReg": "2000-04-01", 
    "description": "Objective: Nilvadipine, a calcium antagonist, has been shown to have antioxidant activity in vitro, but its effect on in vivo oxidation has not been assessed. The aim of this study was to investigate the antioxidant effect of this agent in vivo. The ratios of 7-keto cholestadien to cholesterol are believed to be an available marker of lipid peroxidation. Using these ratios, we have assessed the antioxidant effect of nilvadipine on low-density lipoprotein (LDL) in hypertensive patients with high risk of atherosclerosis. The risk factors of atherosclerosis may involve oxidation of LDL.Methods: Fifteen healthy subjects (seven females and eight males aged 35\u201372\u2009years, mean\u2009\u00b1\u2009SD=55.3\u2009\u00b1 13.8\u2009years) and fifteen hypertensive patients (seven females and eight males aged 45\u201380\u2009years, mean\u2009\u00b1 SD\u2009= 60.2\u2009\u00b1\u200911.8\u2009years) were recruited. Patients were treated orally with nilvadipine (4\u2009mg b.i.d.) for 4\u2009weeks. Cholesterol oxidation levels of LDL in patients before and after nilvadipine therapy and healthy subjects were studied.Results: The ratios of 7-keto cholestadien to cholesterol in LDL of hypertensive patients before and 4\u2009weeks after nilvadipine treatment and in healthy subjects were 6.5\u2009\u00b1\u20091.6% (mean\u2009\u00b1\u2009SD), 3.8\u2009\u00b1\u20091.2%, and 0.2\u2009\u00b1 0.1%, respectively. There were significantly (P\u2009<\u20090.001) increased levels of cholesterol oxidation in LDL in patients with hypertension both before and after nilvadipine treatment compared with healthy subjects. However, there was a significantly (P\u2009<\u20090.001) decreased level of cholesterol oxidation in LDL in patients after nilvadipine treatment compared with patients before nilvadipine treatment.Conclusion: Our data showed that nilvadipine may protect LDL cholesterol from in vivo oxidation in hypertensive patients with high risk of atherosclerosis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002280050717", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "56"
      }
    ], 
    "keywords": [
      "low-density lipoprotein", 
      "hypertensive patients", 
      "nilvadipine treatment", 
      "healthy subjects", 
      "risk factors", 
      "high risk", 
      "low-density lipoprotein cholesterol", 
      "antioxidant effects", 
      "vivo oxidation", 
      "oxidation of LDL", 
      "lipoprotein cholesterol", 
      "LDL cholesterol", 
      "calcium antagonists", 
      "patients", 
      "atherosclerosis", 
      "nilvadipine", 
      "lipid peroxidation", 
      "cholesterol", 
      "cholesterol oxidation", 
      "available markers", 
      "treatment", 
      "subjects", 
      "weeks", 
      "risk", 
      "hypertension", 
      "therapy", 
      "antagonist", 
      "levels", 
      "lipoproteins", 
      "antioxidant activity", 
      "factors", 
      "peroxidation", 
      "effect", 
      "vivo", 
      "markers", 
      "aim", 
      "agents", 
      "ratio", 
      "activity", 
      "study", 
      "data", 
      "oxidation level", 
      "oxidation", 
      "cholestadien", 
      "Cholesterol oxidation levels", 
      "nilvadipine therapy"
    ], 
    "name": "Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis", 
    "pagination": "35-41", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046077486"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002280050717"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10853875"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002280050717", 
      "https://app.dimensions.ai/details/publication/pub.1046077486"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_324.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002280050717"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002280050717'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002280050717'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002280050717'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002280050717'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      22 PREDICATES      91 URIs      80 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002280050717 schema:about N03c4a841386040c5a5c52c0c39fdc917
2 N0d57ab6307ad45ab9f4ede3271805afe
3 N3cd59cff405e47ecbc3577d91c683f69
4 N51b827c8582143fca0bef036fd323042
5 N7f444e1f7bc9459e9c51403629f39307
6 N7fb1294dcaf6442db654b0cfb43941fd
7 N86e8bb9fdb90457fb778e74015504f80
8 Na190e29d1f794e199564bb3b76299a8f
9 Nb2105c8afc1946debdd0f390b04ac740
10 Nb71d83f9a0674b7d8816feb9acc94074
11 Nbdf976af66d8455a9403b880c56df84e
12 Nce2c9db5615b47fa95f3773cf006c535
13 Ne45ef5301376443eb4e24144f84e442c
14 Nee8576e750a649bc9eb2263f1e24ec12
15 Nf5ba9849e08149a5aa0bcf0767fe6a90
16 anzsrc-for:11
17 anzsrc-for:1102
18 anzsrc-for:1103
19 schema:author N680316c72aeb4be3bdc3007d22eba4ba
20 schema:citation sg:pub.10.1007/bf00051106
21 sg:pub.10.1007/bf02940252
22 schema:datePublished 2000-04
23 schema:datePublishedReg 2000-04-01
24 schema:description Objective: Nilvadipine, a calcium antagonist, has been shown to have antioxidant activity in vitro, but its effect on in vivo oxidation has not been assessed. The aim of this study was to investigate the antioxidant effect of this agent in vivo. The ratios of 7-keto cholestadien to cholesterol are believed to be an available marker of lipid peroxidation. Using these ratios, we have assessed the antioxidant effect of nilvadipine on low-density lipoprotein (LDL) in hypertensive patients with high risk of atherosclerosis. The risk factors of atherosclerosis may involve oxidation of LDL.Methods: Fifteen healthy subjects (seven females and eight males aged 35–72 years, mean ± SD=55.3 ± 13.8 years) and fifteen hypertensive patients (seven females and eight males aged 45–80 years, mean ± SD = 60.2 ± 11.8 years) were recruited. Patients were treated orally with nilvadipine (4 mg b.i.d.) for 4 weeks. Cholesterol oxidation levels of LDL in patients before and after nilvadipine therapy and healthy subjects were studied.Results: The ratios of 7-keto cholestadien to cholesterol in LDL of hypertensive patients before and 4 weeks after nilvadipine treatment and in healthy subjects were 6.5 ± 1.6% (mean ± SD), 3.8 ± 1.2%, and 0.2 ± 0.1%, respectively. There were significantly (P < 0.001) increased levels of cholesterol oxidation in LDL in patients with hypertension both before and after nilvadipine treatment compared with healthy subjects. However, there was a significantly (P < 0.001) decreased level of cholesterol oxidation in LDL in patients after nilvadipine treatment compared with patients before nilvadipine treatment.Conclusion: Our data showed that nilvadipine may protect LDL cholesterol from in vivo oxidation in hypertensive patients with high risk of atherosclerosis.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf N4367b5e6a16f4298ae31d677922e57b8
29 Ne14fcd54df964fe2af02cbea59a62ffe
30 sg:journal.1054337
31 schema:keywords Cholesterol oxidation levels
32 LDL cholesterol
33 activity
34 agents
35 aim
36 antagonist
37 antioxidant activity
38 antioxidant effects
39 atherosclerosis
40 available markers
41 calcium antagonists
42 cholestadien
43 cholesterol
44 cholesterol oxidation
45 data
46 effect
47 factors
48 healthy subjects
49 high risk
50 hypertension
51 hypertensive patients
52 levels
53 lipid peroxidation
54 lipoprotein cholesterol
55 lipoproteins
56 low-density lipoprotein
57 low-density lipoprotein cholesterol
58 markers
59 nilvadipine
60 nilvadipine therapy
61 nilvadipine treatment
62 oxidation
63 oxidation level
64 oxidation of LDL
65 patients
66 peroxidation
67 ratio
68 risk
69 risk factors
70 study
71 subjects
72 therapy
73 treatment
74 vivo
75 vivo oxidation
76 weeks
77 schema:name Nilvadipine protects low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis
78 schema:pagination 35-41
79 schema:productId N51621b1d02aa4aa8a7bf2e54d4cde862
80 Na288756de2cf4fbaad143cf81ac23f18
81 Ncb46f88c224144f78cc23fee8926b072
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046077486
83 https://doi.org/10.1007/s002280050717
84 schema:sdDatePublished 2022-01-01T18:10
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher Nd6f2acfce3da4766acd0a8f4a09d6143
87 schema:url https://doi.org/10.1007/s002280050717
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N03c4a841386040c5a5c52c0c39fdc917 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Arteriosclerosis
93 rdf:type schema:DefinedTerm
94 N0d57ab6307ad45ab9f4ede3271805afe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Male
96 rdf:type schema:DefinedTerm
97 N111b63dee7de424e93d2efdfac5b59c1 rdf:first sg:person.01303203706.66
98 rdf:rest Na10bd4ae6d7d47a0a4784bd0cd9e2d8b
99 N3cd59cff405e47ecbc3577d91c683f69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Adult
101 rdf:type schema:DefinedTerm
102 N4367b5e6a16f4298ae31d677922e57b8 schema:volumeNumber 56
103 rdf:type schema:PublicationVolume
104 N51621b1d02aa4aa8a7bf2e54d4cde862 schema:name doi
105 schema:value 10.1007/s002280050717
106 rdf:type schema:PropertyValue
107 N51b827c8582143fca0bef036fd323042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Aged
109 rdf:type schema:DefinedTerm
110 N680316c72aeb4be3bdc3007d22eba4ba rdf:first sg:person.01052526706.24
111 rdf:rest N111b63dee7de424e93d2efdfac5b59c1
112 N7f444e1f7bc9459e9c51403629f39307 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Hypertension
114 rdf:type schema:DefinedTerm
115 N7fb1294dcaf6442db654b0cfb43941fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Case-Control Studies
117 rdf:type schema:DefinedTerm
118 N86e8bb9fdb90457fb778e74015504f80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Antihypertensive Agents
120 rdf:type schema:DefinedTerm
121 Na10bd4ae6d7d47a0a4784bd0cd9e2d8b rdf:first sg:person.0625412514.00
122 rdf:rest rdf:nil
123 Na190e29d1f794e199564bb3b76299a8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Middle Aged
125 rdf:type schema:DefinedTerm
126 Na288756de2cf4fbaad143cf81ac23f18 schema:name dimensions_id
127 schema:value pub.1046077486
128 rdf:type schema:PropertyValue
129 Nb2105c8afc1946debdd0f390b04ac740 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Oxidative Stress
131 rdf:type schema:DefinedTerm
132 Nb71d83f9a0674b7d8816feb9acc94074 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Aged, 80 and over
134 rdf:type schema:DefinedTerm
135 Nbdf976af66d8455a9403b880c56df84e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Cholesterol, LDL
137 rdf:type schema:DefinedTerm
138 Ncb46f88c224144f78cc23fee8926b072 schema:name pubmed_id
139 schema:value 10853875
140 rdf:type schema:PropertyValue
141 Nce2c9db5615b47fa95f3773cf006c535 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 Nd6f2acfce3da4766acd0a8f4a09d6143 schema:name Springer Nature - SN SciGraph project
145 rdf:type schema:Organization
146 Ne14fcd54df964fe2af02cbea59a62ffe schema:issueNumber 1
147 rdf:type schema:PublicationIssue
148 Ne45ef5301376443eb4e24144f84e442c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Risk Factors
150 rdf:type schema:DefinedTerm
151 Nee8576e750a649bc9eb2263f1e24ec12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Nifedipine
153 rdf:type schema:DefinedTerm
154 Nf5ba9849e08149a5aa0bcf0767fe6a90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Female
156 rdf:type schema:DefinedTerm
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
161 schema:name Cardiorespiratory Medicine and Haematology
162 rdf:type schema:DefinedTerm
163 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
164 schema:name Clinical Sciences
165 rdf:type schema:DefinedTerm
166 sg:journal.1054337 schema:issn 0031-6970
167 1432-1041
168 schema:name European Journal of Clinical Pharmacology
169 schema:publisher Springer Nature
170 rdf:type schema:Periodical
171 sg:person.01052526706.24 schema:affiliation grid-institutes:grid.413722.1
172 schema:familyName Inouye
173 schema:givenName M.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052526706.24
175 rdf:type schema:Person
176 sg:person.01303203706.66 schema:affiliation grid-institutes:grid.31432.37
177 schema:familyName Mio
178 schema:givenName T.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303203706.66
180 rdf:type schema:Person
181 sg:person.0625412514.00 schema:affiliation grid-institutes:grid.31432.37
182 schema:familyName Sumino
183 schema:givenName K.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625412514.00
185 rdf:type schema:Person
186 sg:pub.10.1007/bf00051106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047626214
187 https://doi.org/10.1007/bf00051106
188 rdf:type schema:CreativeWork
189 sg:pub.10.1007/bf02940252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051361641
190 https://doi.org/10.1007/bf02940252
191 rdf:type schema:CreativeWork
192 grid-institutes:grid.31432.37 schema:alternateName Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP
193 schema:name Department of Public Health, Kobe University School of Medicine, 7-chome, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, JP
194 rdf:type schema:Organization
195 grid-institutes:grid.413722.1 schema:alternateName Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Akebono-cho 1070, Nishi-ku, Kobe 651-2181, Japan Tel.: +81-78-9272727; Fax: +81-78-9259203, JP
196 schema:name Department of Internal Medicine, Hyogo Rehabilitation Center Hospital, Akebono-cho 1070, Nishi-ku, Kobe 651-2181, Japan Tel.: +81-78-9272727; Fax: +81-78-9259203, JP
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...